ProMIS Neurosciences Highlights PMN310's Targeting Capabilities for Alzheimer’s Treatment
CAMBRIDGE, Massachusetts and TORONTO, Ontario — ProMIS Neurosciences Inc. (NASDAQ: PMN), a prominent player in the biotechnology sector, has made noteworthy advancements in antibody therapeutics. Their mission centers around tackling neurodegenerative disorders, particularly Alzheimer’s disease (AD), with their promising candidate, PMN310. Recent updates were shared during an engaging oral presentation at the 4th International Conference on Cognitive & Behavioral Neurosciences (ICBN), which showcased PMN310's exceptional ability to target toxic oligomers specifically associated with AD.
What Are Toxic Oligomers in Alzheimer’s Disease?
Research has revealed that the most harmful forms of amyloid-beta (Aß) in Alzheimer’s disease are actually soluble toxic oligomers, rather than the traditionally viewed insoluble fibrils or monomers. To effectively treat Alzheimer’s, therapeutic antibodies must be capable of accurately identifying these toxic species while steering clear of the non-toxic ones. PMN310 is designed with this precision in mind, aiming to effectively target these harmful substances and thereby enhancing treatment outcomes.
Key Insights from the ICBN Presentation
“Our presentation highlighted PMN310’s unique selectivity for toxic oligomers,” noted Johanne Kaplan, Ph.D., Chief Development Officer at ProMIS Neurosciences. “This characteristic is vital, particularly when considering the potential risk of amyloid-related imaging abnormalities (ARIA) associated with plaque-binding antibodies.” Kaplan's insight underscores how PMN310's thoughtful design aims to reduce side effects while effectively targeting dangerous amyloid-beta oligomers.
Research Findings on PMN310's Effectiveness
The research involved studying the interaction of PMN310 with other Aß-directed antibodies in an oligomer-rich brain extract sourced from Alzheimer’s patients. Through surface plasmon resonance, researchers found that PMN310 showed minimal interaction with Aß monomers, affirming its strong binding affinity to toxic oligomers. Furthermore, immunohistochemistry analyses revealed that PMN310 does not bind to amyloid plaques or vascular deposits, reinforcing its distinct therapeutic profile.
Details of the ICBN Oral Presentation
The oral presentation covered essential aspects of PMN310, focusing on the following:
Title: Distinguishing between amyloid-beta directed antibodies: Ability of PMN310 to target toxic oligomers despite competing species
Date/Time of Virtual Presentation: Friday, September 13 at 2:00pm WEST (6:00am PT / 9:00am ET)
Authors: Johanne Kaplan, Ebrima Gibbs, Juliane Coutts, Beibei Zhao, Neil R. Cashman
The Future of PMN310 and Company Developments
Recently, ProMIS Neurosciences shared encouraging topline results from its Phase 1a clinical trial of PMN310 in humans. The outcomes regarding safety, tolerability, and pharmacokinetics have been positive, setting a solid stage for further clinical developments. ProMIS is hopeful about moving forward to a Phase 1b study in the coming quarters, which could fast-track PMN310 as a potential treatment for Alzheimer’s disease.
What Exactly is PMN310?
PMN310 is a humanized monoclonal antibody designed to specifically target and neutralize soluble amyloid beta oligomers (A?Os). This approach is based on the understanding that A?Os are more harmful than A? monomers and amyloid plaques. Studies have indicated that these oligomers can negatively impact neuronal function and contribute to neurodegeneration. By focusing on these toxic oligomers, PMN310 aims to reduce the associated risks of Alzheimer’s disease progression.
Overview of ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is at the cutting edge of biotechnological innovation, primarily focusing on antibody therapies designed to combat harmful misfolded proteins across various neurodegenerative diseases, including Alzheimer’s, ALS, and MSA. Their proprietary discovery platform, ProMIS™, employs computational techniques to identify unique 'Disease Specific Epitopes' found on misfolded proteins, ensuring that antibody development is tailored for maximal therapeutic impact.
Frequently Asked Questions
What is PMN310 and why is it important?
PMN310 is a groundbreaking monoclonal antibody that targets toxic soluble amyloid-beta oligomers, which are significant contributors to Alzheimer’s disease progression.
Where was PMN310's information presented?
The information on PMN310 was presented at the 4th International Conference on Cognitive & Behavioral Neurosciences in Lisbon, highlighting its unique abilities.
How does PMN310 compare to other treatments?
PMN310 shows greater selectivity for toxic oligomers while avoiding non-toxic forms, which may indicate superior effectiveness compared to traditional therapies.
What’s next for PMN310?
The company plans to advance into a Phase 1b clinical study soon, following the success of earlier trial results.
Where can I learn more about ProMIS Neurosciences?
For further details, you can visit the ProMIS Neurosciences website or reach out to their media inquiries via the provided email address.
